


L1 STR



VPA 10-2/1/6/5 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 6
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

=> s l1 ful
FULL SEARCH INITIATED 17:20:17 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1201 TO ITERATE

100.0% PROCESSED 1201 ITERATIONS 322 ANSWERS
SEARCH TIME: 00.00.01

L3 322 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

	SINCE FILE ENTRY	TOTAL SESSION
	179.74	180.37

FILE 'CAPLUS' ENTERED AT 17:20:20 ON 08 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Jul 2008 VOL 149 ISS 2
FILE LAST UPDATED: 7 Jul 2008 (20080707/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 13

L4 32 L3

=> d bib 1-32

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:593290 CAPLUS
DN 147:202903
TI Exploring Peptide-likeness of Active Molecules Using 2D Fingerprint
Methods
AU Eckert, Hanna; Bajorath, Juergen
CS Department of Life Science Informatics, Rheinische Friedrich-Wilhelms-
Universitaet, Bonn, D-53113, Germany
SO Journal of Chemical Information and Modeling (2007), 47(4), 1366-1378
CODEN: JCISD8; ISSN: 1549-9596
PB American Chemical Society
DT Journal
LA English
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:505925 CAPLUS
DN 146:317191
TI Synthetic studies of tokaramide A and miraziridine A isolated from marine
sponge Theonella aff. mirabilis
AU Konno, Hiroyuki; Kubo, Kanako; Makabe, Hidefumi; Fujii, Nobutaka; Nosaka,
Kazuto; Akaji, Kenichi
CS Department of Chemistry, Graduate School of Medical Science, Kyoto
Prefectural University of Medicine, Kita-ku, Kyoto, 603-8334, Japan
SO Peptide Science (2006), Volume Date 2005, 42nd, 47-50
CODEN: PSCIFQ; ISSN: 1344-7661
PB Japanese Peptide Society
DT Journal
LA English
OS CASREACT 146:317191
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:124019 CAPLUS
DN 144:365177
TI Exploring the Sn Binding Pockets in Gingipains by Newly Developed
Inhibitors: Structure-Based Design, Chemistry, and Activity
AU Bialas, Arkadiusz; Grembecka, Jolanta; Krowarsch, Daniel; Otlewski, Jacek;
Potempa, Jan; Mucha, Artur
CS Department of Bioorganic Chemistry Faculty of Chemistry, Wroclaw
University of Technology, Woroclaw, 50-370, Pol.
SO Journal of Medicinal Chemistry (2006), 49(5), 1744-1753
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 144:365177
RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2003:737774 CAPLUS
 DN 139:246221
 TI Preparation of acylaminopiperidine-1-carboxamidines as inhibitors of
 plasma kallikrein
 IN Evans, David Michael
 PA Ferring BV, Neth.
 SO PCT Int. Appl., 35 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003076458	A2	20030918	WO 2003-GB908	20030304
	WO 2003076458	A3	20031106		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
	PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,				
	UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	TW 283685	B	20070711	TW 2003-92104061	20030226
	CA 2478099	A1	20030918	CA 2003-2478099	20030304
	AU 2003208471	A1	20030922	AU 2003-208471	20030304
	AU 2003208471	B2	20060928		
	EP 1483284	A2	20041208	EP 2003-706759	20030304
	EP 1483284	B1	20060719		
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1639186	A	20050713	CN 2003-805401	20030304
	JP 2005533750	T	20051110	JP 2003-574673	20030304
	NZ 534891	A	20060331	NZ 2003-534891	20030304
	AT 333463	T	20060815	AT 2003-706759	20030304
	ES 2264523	T3	20070101	ES 2003-706759	20030304
	RU 2301225	C2	20070620	RU 2004-126610	20030304
	ZA 2004006856	A	20050920	ZA 2004-6856	20040827
	IN 2004DN02544	A	20050401	IN 2004-DN2544	20040831
	NO 2004003695	A	20041007	NO 2004-3695	20040903
	MX 2004PA08523	A	20041206	MX 2004-PA8523	20040903
	HK 1072265	A1	20060915	HK 2005-104336	20050524
	US 20060052313	A1	20060309	US 2005-506535	20050705
PRAI	GB 2002-5527	A	20020308		
	WO 2003-GB908	W	20030304		
OS	MARPAT 139:246221				

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2003:575440 CAPLUS
 DN 140:89759
 TI Isolation and characterization of a novel and potent inhibitor of
 Arg-gingipain from Streptomyces sp. strain FA-70
 AU Kadowaki, Tomoko; Kitano, Shizuo; Baba, Atsuyo; Takii, Ryosuke; Hashimoto,
 Munetaka; Katunuma, Nobuhiko; Yamamoto, Kenji
 CS Department of Pharmacology, Graduate School of Dental Science, Kyushu
 University, Fukuoka, 812-8582, Japan
 SO Biological Chemistry (2003), 384(6), 911-920

CODEN: BICHF3; ISSN: 1431-6730
PB Walter de Gruyter GmbH & Co. KG
DT Journal
LA English
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:203392 CAPLUS
DN 138:188079
TI Preparation of peptides as inhibitors of serine protease activity of
matriptase or MTSP1
IN Semple, Joseph E.; Coombs, Gary S.; Reiner, John E.; Ong, Edgar O.;
Araldi, Gian Luca
PA USA
SO U.S. Pat. Appl. Publ., 34 pp., Cont.-in-part of Appl. No. PCT/US01/28137.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20030050251	A1	20030313	US 2002-92004	20020305
	US 7157596	B2	20070102		
	US 6797504	B1	20040928	US 2000-657986	20000908
	WO 2002020475	A2	20020314	WO 2001-US28137	20010907
	WO 2002020475	A3	20030814		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2000-657986	A2	20000908		
	WO 2001-US28137	A2	20010907		

OS MARPAT 138:188079
RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:859258 CAPLUS
DN 138:120902
TI Involvement of tissue kallikrein but not plasma kallikrein in the
development of symptoms mediated by endogenous kinins in acute
pancreatitis in rats
AU Griesbacher, Thomas; Rainer, Irmgard; Tiran, Beate; Evans, D. Michael
CS Institute for Experimental and Clinical Pharmacology, University of Graz,
Graz, A-8010, Austria
SO British Journal of Pharmacology (2002), 137(5), 692-700
CODEN: BJPCBM; ISSN: 0007-1188
PB Nature Publishing Group
DT Journal
LA English
RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:609967 CAPLUS
 DN 137:140782
 TI Preparation of peptides as inhibitors of urokinase and blood vessel formation
 IN Brunck, Terence K.; Tamura, Susan Y.
 PA Corvas International, Inc., USA
 SO U.S., 68 pp., Cont. of U.S. Ser. No. 121,921.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6432922	B1	20020813	US 1999-359929	19990722
	US 6576613	B1	20030610	US 1998-121921	19980724
PRAI	US 1998-121921	A2	19980724		
OS	MARPAT 137:140782				
RE.CNT	55	THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L4 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2002:185072 CAPLUS
 DN 136:232549
 TI Preparation of peptides as inhibitors of serine protease activity of matriptase or MTSP1
 IN Duncan, David F.; Madison, Edwin L.; Semple, Joseph Edward; Coombs, Gary Samuel; Reiner, John Eugene; Ong, Edgar O.; Araldi, Gian Luca
 PA Corvas International, Inc., USA
 SO PCT Int. Appl., 82 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002020475	A2	20020314	WO 2001-US28137	20010907
	WO 2002020475	A3	20030814		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 6797504	B1	20040928	US 2000-657986	20000908
	CA 2422157	A1	20020314	CA 2001-2422157	20010907
	AU 2001088922	A	20020322	AU 2001-88922	20010907
	EP 1353902	A2	20031022	EP 2001-968692	20010907
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004509085	T	20040325	JP 2002-525098	20010907
	US 20030050251	A1	20030313	US 2002-92004	20020305
	US 7157596	B2	20070102		
PRAI	US 2000-657986	A	20000908		
	WO 2001-US28137	W	20010907		
OS	MARPAT 136:232549				

L4 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2001:380438 CAPLUS
 DN 135:24657
 TI Selective cellular targeting: multifunctional delivery vehicles
 IN Glazier, Arnold
 PA Drug Innovation & Design, Inc., USA
 SO PCT Int. Appl., 981 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001036003	A2	20010525	WO 2000-US31262	20001114
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2391534	A1	20010525	CA 2000-2391534	20001114
	AU 2001016075	A	20010530	AU 2001-16075	20001114
	EP 1255567	A1	20021113	EP 2000-978631	20001114
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 20030138432	A1	20030724	US 2000-738625	20001215
PRAI	US 1999-165485P	P	19991115		
	US 2000-239478P	P	20001011		
	US 2000-241937P	P	20001020		
	WO 2000-US31262	W	20001114		
	US 2000-712465	B1	20001115		

L4 ANSWER 11 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2001:283983 CAPLUS
 DN 134:311435
 TI Preparation of inhibitors of factor Xa having an arginine or arginine aldehyde mimic
 IN Semple, Joseph Edward; Brunck, Terence Kevin; Levy, Odile Esther; Tamura, Susan Y.
 PA Corvas International, Inc., USA
 SO PCT Int. Appl., 163 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001027141	A1	20010419	WO 2000-US27615	20001006
	W: CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	US 1999-414903	A	19991008		
OS	MARPAT 134:311435				
RE.CNT	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L4 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2000:719702 CAPLUS
 DN 134:65800

TI Novel, potent and selective chimeric FXa inhibitors featuring hydrophobic
p1-ketoamide moieties
AU Semple, J. E.; Levy, O. E.; Minami, N. K.; Owens, T. D.; Siev, D. V.
CS Department of Medicinal Chemistry, Corvas International, Inc., San Diego,
CA, 92121, USA
SO Bioorganic & Medicinal Chemistry Letters (2000), 10(20), 2305-2309
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 134:65800
RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:380083 CAPLUS
DN 133:144710
TI Synthesis and biological activity of peptidyl aldehyde urokinase
inhibitors
AU Tamura, Susan Y.; Weinhouse, Michael I.; Roberts, Christopher A.; Goldman,
Erick A.; Masukawa, Kevin; Anderson, Susanne M.; Cohen, Cheryl R.;
Bradbury, Annette E.; Bernardino, Vernon T.; Dixon, Steven A.; Ma, Michael
G.; Nolan, Thomas G.; Brunck, Terence K.
CS Department of Medicinal Chemistry, Corvas International, Inc., San Diego,
CA, 92121, USA
SO Bioorganic & Medicinal Chemistry Letters (2000), 10(9), 983-987
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:269116 CAPLUS
DN 133:43799
TI Guanylpiperidine peptidomimetics: potent and selective bis-cation
inhibitors of factor Xa
AU Tamura, Susan Y.; Levy, Odile E.; Uong, Theresa H.; Reiner, John E.;
Goldman, Erick A.; Ho, Jonathan Z.; Cohen, Cheryl R.; Bergum, Peter W.;
Nutt, Ruth F.; Brunck, Terence K.; Semple, J. Edward
CS Department of Medicinal Chemistry, Corvas International, Inc., San Diego,
CA, 92121, USA
SO Bioorganic & Medicinal Chemistry Letters (2000), 10(8), 745-749
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 133:43799
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:219109 CAPLUS
DN 132:251428
TI Preparation of peptidyl inhibitors of factor Xa for treatment of
coagulation disorders
IN Marlowe, Charles K.; Scarborough, Robert M.; Laibelman, Alan M.; Sinha,
Uma; Zhu, Bing-Yan
PA COR Therapeutics, Inc., USA
SO U.S., 26 pp.

CODEN: USXXAM

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 6046169	A	20000404	US 1995-486386	19950607
PRAI	US 1995-486386		19950607		

OS MARPAT 132:251428

RE.CNT 75 THERE ARE 75 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:151495 CAPLUS
DN 132:203169
TI FA-70 C1 and its salts as cathepsin protease and Arg-gingipain inhibitors
for treatment of periodontal diseases
IN Kitano, Shizuo; Yoshida, Kenichiro; Katsunuma, Nobuhiko; Yamamoto, Kenji
PA Taiho Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 16 pp.
CODEN: JKXXAF

DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 2000072797	A	20000307	JP 1998-254540	19980824
	JP 3643925	B2	20050427		
PRAI	JP 1998-254540		19980824		

L4 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:113118 CAPLUS
DN 132:152140
TI Preparation of N-substituted glycine derivatives as enzyme inhibitors
IN Abelman, Matthew Mark; Miller, Todd Anthony; Nutt, Ruth Foelsche
PA Corvas International, Inc., USA
SO U.S., 67 pp., Cont.-in-part of U.S. 5,696,231.
CODEN: USXXAM

DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 6025472	A	20000215	US 1995-484509	19950607
	US 5696231	A	19971209	US 1994-361794	19941221
	CA 2207373	A1	19960627	CA 1995-2207373	19951221
	WO 9619493	A1	19960627	WO 1995-US16866	19951221
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9646086	A	19960710	AU 1996-46086	19951221
	AU 716995	B2	20000316		
	EP 801654	A1	19971022	EP 1995-944234	19951221
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV				
	BR 9510264	A	19971104	BR 1995-10264	19951221
	CN 1171116	A	19980121	CN 1995-196925	19951221

	HU 77524	A2	19980528	HU 1998-71	19951221
	JP 10512550	T	19981202	JP 1995-520031	19951221
	NZ 300829	A	20010330	NZ 1995-300829	19951221
PRAI	US 1994-361794	A2	19941221		
	US 1995-484509	A	19950607		
	WO 1995-US16866	W	19951221		

OS MARPAT 132:152140

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2000:84824 CAPLUS

DN 132:137731

TI Preparation of peptides as inhibitors of urokinase and blood vessel formation

IN Brunck, Terence K.; Tamura, Susan Y.

PA Corvas International, Inc., USA

SO PCT Int. Appl., 194 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000005245	A2	20000203	WO 1999-US16577	19990722
	WO 2000005245	A3	20000420		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6576613	B1	20030610	US 1998-121921	19980724
	CA 2338524	A1	20000203	CA 1999-2338524	19990722
	AU 9950058	A	20000214	AU 1999-50058	19990722
	AU 772024	B2	20040408		
	EP 1100814	A2	20010523	EP 1999-934173	19990722
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	JP 2002521386	T	20020716	JP 2000-561201	19990722
	NZ 509400	A	20031219	NZ 1999-509400	19990722
PRAI	US 1998-121921	A	19980724		
	WO 1999-US16577	W	19990722		

OS MARPAT 132:137731

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2000:84767 CAPLUS

DN 132:137729

TI Preparation of derivatized amino-aldehyde resins useful for solid-phase synthesis of peptides, peptidyl aldehydes, and peptidomimetic compounds

IN Siev, Daniel V.; Semple, J. Edward; Roberts, Christopher A.

PA Corvas International Inc., USA

SO PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

PI WO 2000005208 A1 20000203 WO 1999-US16901 19990723
W: JP
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE
EP 1100782 A1 20010523 EP 1999-938805 19990723
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI
JP 2002521364 T 20020716 JP 2000-561165 19990723
PRAI US 1998-122009 A 19980724
WO 1999-US16901 W 19990723
OS CASREACT 132:137729; MARPAT 132:137729
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:9751 CAPLUS
DN 132:216542
TI Exploratory solid-phase synthesis of factor Xa inhibitors: discovery and
application of P3-heterocyclic amides as novel types of non-basic arginine
surrogates
AU Ho, Jonathan Z.; Levy, Odile E.; Gibson, Tony S.; Nguyen, Khanh; Semple,
J. Edward
CS Department of Medicinal Chemistry, Corvas International, Inc., San Diego,
CA, 92121, USA
SO Bioorganic & Medicinal Chemistry Letters (1999), 9(24), 3459-3464
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:484456 CAPLUS
DN 129:213364
OREF 129:43263a,43266a
TI Peptide aldehyde inhibitors of the kallikreins: an investigation of
subsite interactions with tripeptides containing structural variations at
the amino terminus
AU Garrett, G. S.; Correa, P. E.; Mcphail, S. J.; Tornheim, K.; Burton, J.
A.; Eickhoff, D. J.; Engerholm, G. G.; Mciver, J. M.
CS Corporate Research Division, Procter and Gamble Company, Miami Valley
Laboratories, Cincinnati, OH, 45253-8707, USA
SO Journal of Peptide Research (1998), 52(1), 60-71
CODEN: JPERFA; ISSN: 1397-002X
PB Munksgaard International Publishers Ltd.
DT Journal
LA English
RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:146693 CAPLUS
DN 128:205143
OREF 128:40579a,40582a
TI Preparation of peptidyl inhibitors of factor Xa
IN Marlowe, Charles K.; Scarborough, Robert M.; Laibelman, Alan M.; Sinha,
Uma; Zhu, Bing-yan
PA COR Therapeutics, Inc., USA
SO U.S., 25 pp.
CODEN: USXXAM

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5721214	A	19980224	US 1995-485433	19950607
PRAI	US 1995-485433		19950607		

OS MARPAT 128:205143

RE.CNT 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:121403 CAPLUS

DN 126:131783

OREF 126:25461a

TI Preparation of peptides as inhibitors of factor Xa

IN Marlowe, Charles K.; Scarborough, Robert M.; Laibelman, Alan M.; Sinha, Uma; Zhu, Bing-yan

PA Cor Therapeutics, Inc., USA

SO PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9640743	A2	19961219	WO 1996-US9285	19960605
	WO 9640743	A3	19970123		
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	US 5919765	A	19990706	US 1995-483470	19950607
	CA 2224076	A1	19961219	CA 1996-2224076	19960605
	AU 9665902	A	19961230	AU 1996-65902	19960605
	AU 710408	B2	19990923		
	EP 846125	A2	19980610	EP 1996-925254	19960605
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 11507626	T	19990706	JP 1996-501639	19960605
	ZA 9604753	A	19970227	ZA 1996-4753	19960606
	US 6245743	B1	20010612	US 1998-77001	19980515
PRAI	US 1995-483470	A	19950607		
	WO 1996-US9285	W	19960605		
OS	MARPAT 126:131783				

L4 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1996:527345 CAPLUS

DN 125:196382

OREF 125:36803a,36806a

TI Preparation of peptide aldehydes as inhibitors of factor Xa.

IN Abelman, Matthew Mark; Miller, Todd Anthony; Nutt, Ruth Foelsche

PA Corvas International, Inc., USA

SO PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

PI	WO 9619493	A1	19960627	WO 1995-US16866	19951221
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5696231	A	19971209	US 1994-361794	19941221
	US 6025472	A	20000215	US 1995-484509	19950607
	AU 9646086	A	19960710	AU 1996-46086	19951221
	AU 716995	B2	20000316		
	EP 801654	A1	19971022	EP 1995-944234	19951221
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV				
	BR 9510264	A	19971104	BR 1995-10264	19951221
	JP 10512550	T	19981202	JP 1995-520031	19951221
	NZ 300829	A	20010330	NZ 1995-300829	19951221
PRAI	US 1994-361794	A	19941221		
	US 1995-484509	A	19950607		
	WO 1995-US16866	W	19951221		
OS	MARPAT 125:196382				

L4 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1995:994438 CAPLUS
 DN 124:87806
 OREF 124:16519a,16522a
 TI L-Arginine aldehyde peptide derivatives useful as antithrombotic agents.
 IN Schacht, Aaron Leigh; Smith, Gerald Floyd; Wiley, Michael Robert
 PA Eli Lilly and Co., USA
 SO Eur. Pat. Appl., 51 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 672659	A1	19950920	EP 1995-301390	19950303
	EP 672659	B1	19990107		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5885967	A	19990323	US 1994-206351	19940304
	CA 2143536	A1	19950905	CA 1995-2143536	19950228
	JP 07258287	A	19951009	JP 1995-43903	19950303
	AT 175404	T	19990115	AT 1995-301390	19950303
	ES 2126211	T3	19990316	ES 1995-301390	19950303
	US 6090787	A	20000718	US 1999-267476	19990311
	US 6124277	A	20000926	US 1999-266295	19990311
PRAI	US 1994-206351	A	19940304		
OS	MARPAT 124:87806				

L4 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1994:528474 CAPLUS
 DN 121:128474
 OREF 121:23093a,23096a
 TI 1H NMR study of the diastereomeric forms of the protease inhibitor antipain
 AU Hoebeke, Johan; Busatto-Samsoen, Catherine; Davoust, Daniel; Lebrun, Evelyne
 CS Lab. Enzymol. Protein Chem., Univ. Tours, Tours, 37032, Fr.
 SO Magnetic Resonance in Chemistry (1994), 32(4), 220-4

CODEN: MRCHEG; ISSN: 0749-1581

DT Journal
LA English

L4 ANSWER 27 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1993:626432 CAPLUS

DN 119:226432

OREF 119:40443a,40446a

TI Preparation of tripeptide derivatives as analgesics and antiinflammatories

IN McIver, John McMillan

PA Procter and Gamble Co., USA

SO PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9308211	A1	19930429	WO 1992-US8901	19921019
	W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	AU 9228827	A	19930521	AU 1992-28827	19921019
PRAI	US 1991-780607	A	19911023		
	WO 1992-US8901	A	19921019		
OS	MARPAT 119:226432				

L4 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1993:626427 CAPLUS

DN 119:226427

OREF 119:40443a,40446a

TI Peptide aldehydes as antithrombotic agents

IN Balasubramanian, Neelakantan; St. Laurent, Denis R.

PA Bristol-Myers Squibb Co., USA

SO Eur. Pat. Appl., 55 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 526877	A2	19930210	EP 1992-113284	19920804
	EP 526877	A3	19930407		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CA 2075154	A1	19930207	CA 1992-2075154	19920731
	JP 07242616	A	19950919	JP 1992-206713	19920803
	JP 3273515	B2	20020408		
	US 5380713	A	19950110	US 1994-226219	19940411
PRAI	US 1991-741023	A	19910806		
OS	CASREACT 119:226427; MARPAT 119:226427				

L4 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1990:457085 CAPLUS

DN 113:57085

OREF 113:9645a,9648a

TI Peptide inhibitors of C3 breakdown

AU Peake, P.; Szelke, M.; Jones, D. M.; Singleton, A.; Sueiras-Diaz, J.; Lachmann, P. J.

CS Renal Immunol. Lab., Prince Henry Hosp., Little Bay, 2036, Australia

SO Clinical and Experimental Immunology (1990), 79(3), 454-8

CODEN: CEXIAL; ISSN: 0009-9104

DT Journal
LA English

L4 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1983:34930 CAPLUS

DN 98:34930

OREF 98:5477a,5480a

TI Synthesis of leupeptins and inhibitory studies of proteases

AU Borin, Gianfranco; Chessa, Gavino; Marchiori, Fernando; Mueller-Esterl, Werner

CS Cent. Studi Biopolimeri, CNR, Padua, Italy

SO Pept., Proc. Eur. Pept. Symp., 16th (1981), Meeting Date 1980, 435-40.

Editor(s): Brunfeldt, K. Publisher: Scriptor, Copenhagen, Den.

CODEN: 48NWA3

DT Conference

LA English

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1982:174592 CAPLUS

DN 96:174592

OREF 96:28635a,28638a

TI Synthesis of leupeptins and inhibition of proteinases. I. Inhibition of acrosin and trypsin

AU Borin, Gianfranco; Chessa, Gavino; Cavaggion, Gianfranco; Marchiori, Fernando; Mueller-Esterl, Werner

CS Ist. Chim. Org., Univ. Padova, Padua, 35100, Italy

SO Hoppe-Seyler's Zeitschrift fuer Physiologische Chemie (1981), 362(11), 1435-45

CODEN: HSZPAZ; ISSN: 0018-4888

DT Journal

LA English

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1973:124866 CAPLUS

DN 78:124866

OREF 78:20075a,20078a

TI Alternate synthesis of leupeptins and their analogs

AU Saeki, Hiromichi; Shimada, Yoshikazu; Kawakita, Norio; Shimizu, Bunji; Ohki, Eiji; Maeda, Kenji; Umezawa, Hamao

CS Cent. Res. Lab., Sankyo Co., Ltd., Tokyo, Japan

SO Chemical & Pharmaceutical Bulletin (1973), 21(1), 163-70

CODEN: CPBTAL; ISSN: 0009-2363

DT Journal

LA English

=> s kallikrein?

L5 10039 KALLIKREIN?

=> s 15 and 15

L6 10039 L5 AND L5

=> s 14 and 15

L7 4 L4 AND L5

=> d bib abs hitstr 1-4

L7 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:737774 CAPLUS

DN 139:246221

FAN.CNT 1

NC(=N)N1CCN(CC1)C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[R1])C[R2])C[R3](c2ccccc2)

AB Peptides I [R1 is H, alkyl, R4-CO, R4-O2CCH2, R5-OCO, R5-SO2 (R4 is H, alkyl, Ph and R5 is alkyl, Ph, benzyl); R2 is alkyl, cycloalkyl or cycloalkylalkyl optionally substituted with an alkyl or alkyloxy group, aralkyl optionally substituted with up to three groups chosen from F, Cl, Br, I, OH, alkyl, O-alkyl, O-benzyl, NH2, NO2, NH-acyl, CN, or CF3, or aralkyloxymethyl optionally substituted with up to three groups chosen from F, Cl, Br, OH, alkyl, or O-alkyl; or R1 and R2 together are an o-xylylene group optionally substituted on the aromatic ring by F, Cl, Br, OH, alkyl and O-alkyl; R3 is H, OH, O-alkyl] or pharmaceutically-acceptable salts were prepared as inhibitors of plasma kallikrein. Thus, (2'S,2''R)-4-[2'-[2''-amino-3'''-(4'''-ethoxyphenyl)propanoylamino]-3'-phenylpropanoylamino]piperidine-1-carboxamidine (I; R1, R3 = H, R2 = p-EtOC6H4CH2, stereo not shown) trifluoroacetate was prepared via peptide coupling in solution and showed Ki = 4.5 nM for inhibition of plasma kallikrein.

IT 488821-28-9P 599200-57-4P 599200-58-5P
599200-59-6P 599200-60-9P 599200-61-0P
599200-63-2P 599200-64-3P 599200-65-4P
599200-66-5P 599200-67-6P 599200-68-7P
599200-69-8P 599200-70-1P 599200-71-2P
599200-72-3P 599200-73-4P 599200-74-5P
599200-75-6P 599200-76-7P 599200-77-8P
599200-78-9P 599200-79-0P 599200-80-3P
599200-81-4P 599200-82-5P 599200-83-6P
599200-84-7P 599200-85-8P 599200-86-9P
599200-87-0P 599200-88-1P 599200-89-2P
599200-90-5P 599200-91-6P 599200-92-7P
599200-93-8P 599200-94-9P 599200-95-0P
599200-96-1P 599200-97-2P 599200-98-3P
599200-99-4P 599201-00-0P 599201-01-1P
599201-02-2P 599201-03-3P 599201-04-4P
599201-05-5P 599201-06-6P 599201-07-7P
599201-10-2P 599201-11-3P 599201-12-4P
599201-13-5P 599201-14-6P 599201-15-7P
599201-16-8P 599201-17-9P 599201-18-0P
599201-19-1P 599201-20-4P 600164-95-2P
600164-96-3P 600164-97-4P 600164-98-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptidyl acylaminopiperidinecarboxamidines as inhibitors of plasma kallikrein)

RN 488821-28-9 CAPLUS

CN L-Phenylalaninamide, N-(carboxymethyl)-3-cyclohexyl-D-alanyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-57-4 CAPLUS

CN L-Phenylalaninamide, O-ethyl-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 599200-58-5 CAPLUS


CN L-Phenylalaninamide, O-ethyl-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 599200-57-4

CMF C26 H36 N6 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 599200-59-6 CAPLUS

CN L-Phenylalaninamide, 3-cyclohexyl-N-(2-methoxy-2-oxoethyl)-D-alanyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 599200-60-9 CAPLUS


CN L-Phenylalaninamide, 3-cyclohexyl-N-(2-methoxy-2-oxoethyl)-D-alanyl-N-[1-(aminoiminomethyl)-4-piperidiny]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 599200-59-6

CMF C27 H42 N6 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 599200-61-0 CAPLUS


CN L-Phenylalaninamide, N-(carboxymethyl)-3-cyclohexyl-D-alanyl-N-[1-(aminoiminomethyl)-4-piperidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 488821-28-9

CMF C26 H40 N6 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 599200-63-2 CAPLUS

CN L-Phenylalaninamide, N-benzoyl-O-ethyl-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 599200-62-1
CMF C33 H40 N6 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 599200-64-3 CAPLUS
CN L-Phenylalaninamide, O-ethyl-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidinyl]-β-hydroxy-, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 599200-65-4 CAPLUS
CN L-Phenylalaninamide, O-ethyl-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidinyl]-β-hydroxy-, (βR)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 599200-64-3
CMF C26 H36 N6 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 599200-66-5 CAPLUS
CN L-Phenylalaninamide, O-ethyl-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidinyl]-β-methoxy-, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 599200-67-6 CAPLUS
CN L-Phenylalaninamide, O-ethyl-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidinyl]-β-methoxy-, (βR)-, mono(trifluoroacetate) (9CI)
(CA INDEX NAME)


CRN 599200-66-5
CMF C27 H38 N6 O4

The chemical structure shows a piperidine ring substituted with a guanidine group ($\text{H}_2\text{N}-\text{C}(=\text{NH})-$) and an amide group ($-\text{NH}-\text{C}(=\text{O})-$). The amide nitrogen is connected to a chiral center (C^*) which is also bonded to a methoxy group (MeO), a phenyl group (Ph), and a hydrogen atom (H). This chiral center is further connected to another chiral center (C^*) which is bonded to an amino group (NH_2) and a 4-ethoxyphenyl group ($-\text{CH}_2-\text{C}_6\text{H}_4-\text{OEt}$). Stereochemistry is indicated with wedges and dashes at the chiral centers.

CRN 76-05-1
CMF C2 H F3 O2




Absolute stereochemistry.



RN	599200-69-8	CAPLUS
CN	L-Phenylalaninamide, (2R)-2-cyclohexylglycyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)	


Absolute stereochemistry.



RN 599200-70-1 CAPLUS

CN L-Phenylalaninamide, 3-cyclohexyl-D-alanyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-71-2 CAPLUS

CN Benzenepropanamide, α -[[(2R)-2-amino-4-cyclohexyl-1-oxobutyl]amino]-N-[1-(aminoiminomethyl)-4-piperidinyl]-, (α S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 599200-72-3 CAPLUS

CN L-Phenylalaninamide, 3-(trans-4-ethoxycyclohexyl)-D-alanyl-N-[1-

(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-73-4 CAPLUS

CN Benzenebutanamide, α -amino-N-[(1S)-2-[[1-(aminoiminomethyl)-4-piperidiny]amino]-2-oxo-1-(phenylmethyl)ethyl]-, (α R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-74-5 CAPLUS

CN L-Phenylalaninamide, O-(phenylmethyl)-D-seryl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-75-6 CAPLUS

CN L-Phenylalaninamide, D-phenylalanyl-N-[1-(aminoiminomethyl)-4-piperidiny]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-76-7 CAPLUS

CN L-Phenylalaninamide, 4-propyl-D-phenylalanyl-N-[1-(aminoiminomethyl)-4-
piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-77-8 CAPLUS

CN L-Phenylalaninamide, 4-nitro-D-phenylalanyl-N-[1-(aminoiminomethyl)-4-
piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-78-9 CAPLUS

CN L-Phenylalaninamide, 4-amino-D-phenylalanyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-79-0 CAPLUS

CN L-Phenylalaninamide, 4-iodo-D-phenylalanyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-80-3 CAPLUS

CN L-Phenylalaninamide, 4-fluoro-D-phenylalanyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-81-4 CAPLUS

CN L-Phenylalaninamide, 4-cyano-D-phenylalanyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-82-5 CAPLUS

CN L-Phenylalaninamide, 4-chloro-D-phenylalanyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-83-6 CAPLUS

CN L-Phenylalaninamide, 4-(trifluoromethyl)-D-phenylalanyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-84-7 CAPLUS

CN L-Phenylalaninamide, 4-(acetylamino)-D-phenylalanyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-85-8 CAPLUS

CN L-Phenylalaninamide, 3-fluoro-D-phenylalanyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-86-9 CAPLUS

CN L-Phenylalaninamide, 3,4-dichloro-D-phenylalanyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-87-0 CAPLUS

CN L-Phenylalaninamide, 2,4-dichloro-D-phenylalanyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-88-1 CAPLUS

CN L-Phenylalaninamide, D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-89-2 CAPLUS

CN L-Phenylalaninamide, O-(phenylmethyl)-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-90-5 CAPLUS

CN L-Phenylalaninamide, O-(1,1-dimethylethyl)-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-91-6 CAPLUS

CN L-Phenylalaninamide, O-propyl-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-92-7 CAPLUS

CN L-Phenylalaninamide, O-methyl-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-93-8 CAPLUS

CN L-Phenylalaninamide, O-(1-methylethyl)-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-94-9 CAPLUS

CN L-Phenylalaninamide, O-hexyl-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-95-0 CAPLUS

CN L-Phenylalaninamide, O-ethyl-3,5-diiodo-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-96-1 CAPLUS

CN L-Phenylalaninamide, O-ethyl-N-methyl-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-97-2 CAPLUS

CN L-Phenylalaninamide, O-ethyl-N-(methylsulfonyl)-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599200-98-3 CAPLUS


CN L-Phenylalaninamide, O-ethyl-N-(ethylsulfonyl)-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 599200-99-4 CAPLUS
 CN L-Phenylalaninamide, O-ethyl-N-(phenylsulfonyl)-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 599201-00-0 CAPLUS
 CN L-Phenylalaninamide, N-acetyl-O-ethyl-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 599201-01-1 CAPLUS
 CN L-Phenylalaninamide, O-ethyl-N-(1-oxobutyl)-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599201-02-2 CAPLUS

CN L-Phenylalaninamide, O-ethyl-N-(1-oxopropyl)-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599201-03-3 CAPLUS

CN L-Phenylalaninamide, O-ethyl-N-[(phenylmethoxy)carbonyl]-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599201-04-4 CAPLUS


CN L-Phenylalaninamide, O-ethyl-N-(2-methoxy-2-oxoethyl)-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 599201-05-5 CAPLUS
 CN L-Phenylalaninamide, N-(carboxymethyl)-O-ethyl-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 599201-06-6 CAPLUS
 CN L-Phenylalaninamide, 3-(1-naphthalenyl)-D-alanyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 599201-07-7 CAPLUS
 CN L-Phenylalaninamide, 3-(2-naphthalenyl)-D-alanyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599201-10-2 CAPLUS

CN L-Phenylalaninamide, (β R)- β -hydroxy-D-phenylalanyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599201-11-3 CAPLUS

CN L-Phenylalaninamide, (β R)- β -methoxy-D-phenylalanyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599201-12-4 CAPLUS

CN L-Phenylalaninamide, (β S)- β -hydroxy-D-phenylalanyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599201-13-5 CAPLUS

CN L-Phenylalaninamide, (β S)- β -methoxy-D-phenylalanyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599201-14-6 CAPLUS

CN L-Phenylalaninamide, N-(carboxymethyl)-D-phenylalanyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599201-15-7 CAPLUS

CN L-Phenylalaninamide, N-(2-methoxy-2-oxoethyl)-D-phenylalanyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599201-16-8 CAPLUS

CN L-Phenylalaninamide, 3-cyclohexyl-D-alanyl-N-[1-(aminoiminomethyl)-4-piperidiny]-β-hydroxy-, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 599201-17-9 CAPLUS

CN L-Phenylalaninamide, N-(carboxymethyl)-3-cyclohexyl-D-alanyl-N-[1-(aminoiminomethyl)-4-piperidiny]-β-hydroxy-, (βR)- (9CI) (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 599201-18-0 CAPLUS

CN L-Phenylalaninamide, 3-cyclohexyl-N-(2-methoxy-2-oxoethyl)-D-alanyl-N-[1-(aminoiminomethyl)-4-piperidiny]-β-hydroxy-, (βR)- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 599201-19-1 CAPLUS

CN L-Phenylalaninamide, N-(carboxymethyl)-O-ethyl-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidiny]-β-methoxy-, (βR)- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 599201-20-4 CAPLUS

CN L-Phenylalaninamide, O-ethyl-N-(2-methoxy-2-oxoethyl)-D-tyrosyl-N-[1-(aminoiminomethyl)-4-piperidiny]- β -methoxy-, (β R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 600164-95-2 CAPLUS

CN L-Phenylalaninamide, 3-(4-ethoxycyclohexyl)-D-alanyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 600164-96-3 CAPLUS

CN L-Phenylalaninamide, 3-(decahydro-2-naphthalenyl)-D-alanyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 600164-97-4 CAPLUS

CN L-Phenylalaninamide, N-(carboxymethyl)-3-(decahydro-2-naphthalenyl)-D-alanyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 600164-98-5 CAPLUS

CN L-Phenylalaninamide, 3-(decahydro-2-naphthalenyl)-N-(2-methoxy-2-oxoethyl)-D-alanyl-N-[1-(aminoiminomethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 599201-23-7P 599201-24-8P 599201-25-9P

599201-26-0P 599201-27-1P 599201-30-6P

599201-33-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

```

      (preparation of peptidyl acylaminopiperidinecarboxamides as inhibitors of
      plasma kallikrein)

```

CN L-Phenylalaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-ethyl-D-tyrosyl-N-[1-[[[(phenylmethoxy)carbonyl]amino] [(phenylmethoxy)carbonyl]imino]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)


[illegible]

CN L-Phenylalaninamide, 3-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]-D-alanyl-N-[1-[[[(phenylmethoxy)carbonyl]amino] [(phenylmethoxy)carbonyl]imino]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

CCOC(=O)NC(=N)C1CCN(CC1)NC(=O)[C@H](S[C@@H](C1=CC=CC=C1)C2C(=O)NC(=O)N2C3CCCCC3)C(=O)OC(C)(C)C

CN L-Phenylalaninamide, 3-cyclohexyl-N-(2-methoxy-2-oxoethyl)-D-alanyl-N-[1-
[[[(phenylmethoxy)carbonyl]amino][[(phenylmethoxy)carbonyl]imino]methyl]-4-
piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599201-26-0 CAPLUS

CN L-Phenylalaninamide, N-(carboxymethyl)-3-cyclohexyl-D-alanyl-N-[1-
[[[(phenylmethoxy)carbonyl]amino][[(phenylmethoxy)carbonyl]imino]methyl]-4-
piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599201-27-1 CAPLUS

CN L-Phenylalaninamide, N-benzoyl-O-ethyl-D-tyrosyl-N-[1-
[[[(phenylmethoxy)carbonyl]amino][[(phenylmethoxy)carbonyl]imino]methyl]-4-
piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 599201-30-6 CAPLUS

CN L-Phenylalaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-ethyl-D-tyrosyl-

β -hydroxy-N-[1-[[[(phenylmethoxy)carbonyl]amino][[(phenylmethoxy)carbonyl]imino]methyl]-4-piperidiny]-, (β R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 599201-33-9 CAPLUS

CN Phenylalaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-ethyl-D-tyrosyl- β -methoxy-N-[1-[[[(phenylmethoxy)carbonyl]amino][[(phenylmethoxy)carbonyl]imino]methyl]-4-piperidiny]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:859258 CAPLUS

DN 138:120902

TI Involvement of tissue kallikrein but not plasma kallikrein in the development of symptoms mediated by endogenous kinins in acute pancreatitis in rats

AU Griesbacher, Thomas; Rainer, Irmgard; Tiran, Beate; Evans, D. Michael

CS Institute for Experimental and Clinical Pharmacology, University of Graz, Graz, A-8010, Austria

SO British Journal of Pharmacology (2002), 137(5), 692-700

CODEN: BJPCBM; ISSN: 0007-1188

PB Nature Publishing Group

DT Journal

LA English

AB In order to investigate the mechanism of kinin release leading to vascular

symptoms in acute interstitial-edematous pancreatitis, the novel, selective inhibitors of tissue kallikrein, (2S,2'R)-2-(2'-amino-3'-(4'-chlorophenyl)propanoylamino)-N-(3-guanidinopropyl)-3-(1-naphthyl)propanoamide (FE999024, CH-2856), and of plasma kallikrein, (2'S,2''R)-4-(2'-(2''(carboxymethylamino)-3''-cyclohexyl-propanoyl amino)-3'-phenyl-propanoylamino)piperidine-1-carboxamidin (FE999026, CH-4215), were used in exptl. caerulein-induced pancreatitis in rats. Edema formation and plasma protein extravasation during the 2 h infusion of caerulein were inhibited in a dose-dependent manner by i.p. pretreatment with FE999024 (7-60 $\mu\text{mol kg}^{-1}$) while FE999026 had no effect at the same doses. Haemoconcn. and hypovolemia associated with the pancreatic edema formation during pancreatitis were significantly attenuated by FE999024 at a dose of 20 $\mu\text{mol kg}^{-1}$. The reduction in circulating plasma volume was not affected by FE999026. Accumulation of amylase and lipase in the pancreas was dose-dependently reduced by FE999024 while enzyme activities in the blood serum were increased by FE999024 at 60 $\mu\text{mol kg}^{-1}$ indicating improved enzyme removal from the tissue. Enzyme activities in the tissue and in the blood remained unaffected by FE999026. FE999024 (20 $\mu\text{mol kg}^{-1}$) largely inhibited increased tissue kallikrein-like activity in the pancreas during acute pancreatitis and also strongly attenuated influx of plasma kallikrein into the tissue. FE999026 (20 $\mu\text{mol kg}^{-1}$) significantly inhibited plasma kallikrein-like activity in the pancreas but had no effect on tissue kallikrein-like activity. In conclusion, vascular kinin-mediated symptoms observed during edematous pancreatitis in the rat are caused by the action of tissue kallikrein in the pancreas whereas an involvement of plasma kallikrein seems to be unlikely.


IT 488821-28-9, FE 999026

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(CG 4215, selective plasma kallikrein inhibitor; involvement of tissue kallikrein but not plasma kallikrein in development of symptoms mediated by endogenous kinins in acute pancreatitis in rats)

RN 488821-28-9 CAPLUS

CN L-Phenylalaninamide, N-(carboxymethyl)-3-cyclohexyl-D-alanyl-N-[1-(aminoiminomethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:380438 CAPLUS

DN 135:24657
 TI Selective cellular targeting: multifunctional delivery vehicles
 IN Glazier, Arnold
 PA Drug Innovation & Design, Inc., USA
 SO PCT Int. Appl., 981 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001036003	A2	20010525	WO 2000-US31262	20001114
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2391534	A1	20010525	CA 2000-2391534	20001114
	AU 2001016075	A	20010530	AU 2001-16075	20001114
	EP 1255567	A1	20021113	EP 2000-978631	20001114
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 20030138432	A1	20030724	US 2000-738625	20001215
PRAI	US 1999-165485P	P	19991115		
	US 2000-239478P	P	20001011		
	US 2000-241937P	P	20001020		
	WO 2000-US31262	W	20001114		
	US 2000-712465	B1	20001115		


AB The present invention relates to the compns., methods, and applications of a novel approach to selective cellular targeting. The purpose of this invention is to enable the selective delivery and/or selective activation of effector mols. to target cells for diagnostic or therapeutic purposes. The present invention relates to multi-functional prodrugs or targeting vehicles wherein each functionality is capable of enhancing targeting selectivity, affinity, intracellular transport, activation or detoxification. The present invention also relates to ultralow dose, multiple target, multiple drug chemotherapy and targeted immunotherapy for cancer treatment.

IT 341990-94-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (multifunctional delivery vehicles for selective cellular targeting of drugs)


RN 341990-94-1 CAPLUS

CN L-Alaninamide, N-[41-[2',3'-O-[[3-[[2-(dimethylamino)-2-oxoethoxy]carbonyl]-4-[[2-oxido-5-(phosphonooxy)-1,3,2-dioxaphosphorinan-2-yl]oxy]phenyl]methylene]-N-[(4-nitrophenyl)methyl]-5'-thioadenosin-5'-S-yl]-27-[14-[2',3'-O-[[3-[[2-(dimethylamino)-2-oxoethoxy]carbonyl]-4-[[2-oxido-5-(phosphonooxy)-1,3,2-dioxaphosphorinan-2-yl]oxy]phenyl]methylene]-N-[(4-nitrophenyl)methyl]-5'-thioadenosin-5'-S-yl]-11-oxo-3,6,9-trioxa-12-azatetradec-1-yl]-1,13,26,38-tetraoxo-12-(11-oxo-3,6,9-trioxa-12-azanonadec-1-yl)-3,6,9,15,18,21,24,30,33,36-decaoxa-12,27,39-triazahentetracont-1-yl]-D-seryl-N-[1-(aminoiminomethyl)-2-hydroxy-3-piperidinyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




PAGE 1-C




PAGE 1-D




PAGE 2-A



PAGE 2-B





IT 341550-02-5P 341550-15-0P 341553-10-4P
 341553-11-5P 341990-72-5P 341990-74-7P
 341990-75-8P


RL: PNU (Preparation, unclassified); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(multifunctional delivery vehicles for selective cellular targeting of drugs)

RN 341550-02-5 CAPLUS

CN L-Alaninamide, D-seryl-N-[1-[[[(1-[1,1'-biphenyl]-4-yl-1-methylethoxy)carbonyl]amino]iminomethyl]-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 341550-15-0 CAPLUS


CN L-Alaninamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-D-seryl-N-[1-[[[(1-[1,1'-biphenyl]-4-yl-1-methylethoxy)carbonyl]amino]iminomethyl]-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 341553-10-4 CAPLUS
 CN L-Alaninamide, O-[(1,1-dimethylethyl)dimethylsilyl]-D-seryl-N-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]iminomethyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 341553-11-5 CAPLUS
 CN L-Alaninamide, O-[(1,1-dimethylethyl)dimethylsilyl]-N-[13,26,38-trioxo-27-(11-oxo-3,6,9,12-tetraoxapentadec-14-en-1-yl)-12-(11-oxo-3,6,9-trioxa-12-


azanonadec-1-yl)-3,6,9,15,18,21,24,30,33,36,39-undecaoxa-12,27-
diazadotetracont-41-en-1-yl]-D-seryl-N-[2-[[(1,1-
dimethylethyl)dimethylsilyl]oxy]-1-[[[(9H-fluoren-9-
ylmethoxy)carbonyl]amino]iminomethyl]-3-piperidinyl]- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B





PAGE 1-C




CN L-Alaninamide, N12-[N-[3-[bis(9H-fluoren-9-ylmethoxy)phosphinyl]propyl]-N2-
 [[2-[2-(carboxymethoxy)ethoxy]ethoxy]acetyl]-N-[11-methyl-9-oxo-13-(1-
 piperidinyl)-3,6-dioxo-8,11-diazatridec-1-yl]-L-asparaginy]-N23-[N-[2-[2-
 [[[1,1-dimethylethyl)dimethylsilyl]oxy]amino]-1-methyl-2-oxoethyl]-4-
 methyl-1-oxopentyl]-3-(5,6,7,8-tetrahydro-1-naphthalenyl)-L-alanyl]-23-
 amino-3,6,9,15,18,21-hexaoxa-12-azatricosanoyl-D-seryl-N-[1-[[[(1-[1,1'-
 biphenyl]-4-yl-1-methylethoxy)carbonyl]amino]iminomethyl]-2-[[1,1-
 dimethylethyl)dimethylsilyl]oxy]-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A





PAGE 1-B



PAGE 2-A






RN 341990-74-7 CAPLUS


CN L-Alaninamide, N12-[N-[3-[bis(9H-fluoren-9-ylmethoxy)phosphinyl]propyl]-N-[2-[2-[2-[3-[6-[1-[[3-[1-(9H-fluoren-9-ylmethoxy)carbonyl]-1H-indol-3-yl]-2-methyl-2-[[[(4-nitrophenyl)amino]carbonyl]amino]-1-oxopropyl]amino]methyl]cyclohexyl]-3-pyridinyl]oxy]-1-oxopropyl]amino]ethoxy]ethoxy]ethyl]-L-asparaginy]-N23-[N-[2-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]amino]-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(5,6,7,8-tetrahydro-1-naphthalenyl)-L-alanyl]-23-amino-3,6,9,15,18,21-hexaoxa-12-azatricosanoyl-D-seryl-N-[1-[[[(1-[1,1'-biphenyl]-4-yl-1-methylethoxy)carbonyl]amino]iminomethyl]-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A





PAGE 1-B






PAGE 2-A



PAGE 2-B










Absolute stereochemistry.






IT 341549-84-6P
 RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (multifunctional delivery vehicles for selective cellular targeting of drugs)
 RN 341549-84-6 CAPLUS
 CN L-Alaninamide, O-[(1,1-dimethylethyl)dimethylsilyl]-N-[(2,5-dioxo-1-pyrrolidinyl)oxy]carbonyl]-D-seryl-N-[1-[[[(1-[1,1'-biphenyl]-4-yl-1-methylethoxy)carbonyl]amino]iminomethyl]-2-[(1,1-dimethylethyl)dimethylsilyl]oxy]-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





L7 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1998:484456 CAPLUS
 DN 129:213364
 OREF 129:43263a,43266a
 TI Peptide aldehyde inhibitors of the kallikreins: an investigation
 of subsite interactions with tripeptides containing structural variations
 at the amino terminus
 AU Garrett, G. S.; Correa, P. E.; Mcphail, S. J.; Tornheim, K.; Burton, J.
 A.; Eickhoff, D. J.; Engerholm, G. G.; Mciver, J. M.
 CS Corporate Research Division, Procter and Gamble Company, Miami Valley
 Laboratories, Cincinnati, OH, 45253-8707, USA
 SO Journal of Peptide Research (1998), 52(1), 60-71
 CODEN: JPERFA; ISSN: 1397-002X
 PB Munksgaard International Publishers Ltd.
 DT Journal
 LA English
 AB A series of tripeptide aldehyde derivs. containing variations at the P3
 subsite and the amino terminus has been prepared and evaluated for
 trypsin-like serine protease inhibition. These compds. exhibit strong in
 vitro inhibition of human plasma kallikrein (HPK), porcine
 pancreatic kallikrein (PPK) and human plasmin (HP). As
 suspected from an examination of a related crystal structure, the presence of a
 hydrophobic residue (adamantyl) at the amino terminus dramatically
 improves the binding to PPK. The adamantyl group, however, represents a
 peak in binding; larger residues cause the binding to be reduced, and thus
 are less well accommodated in this subsite. Although both HP and HPK also
 can accept large mol. volume at the amino terminus, they do not exhibit the
 same preference for large residues at this subsite that is demonstrated by
 PPK. Selectivity differences also are observed with P3 subsite substitution;
 with PPK preferring a bulky, but compact side-chain (t-butyl) and HP and
 HPK preferring a more extended (e.g. benzyl) group.
 IT 150906-12-0P 150906-25-5P 150906-26-6P
 150906-31-3P 212334-19-5P 212334-20-8P
 212334-22-0P 212334-24-2P 212334-26-4P
 212334-28-6P 212334-30-0P 212334-32-2P
 212334-34-4P 212334-62-8P 212334-63-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (synthesis of peptide aldehyde inhibitors of kallikreins)
 RN 150906-12-0 CAPLUS
 CN L-Phenylalaninamide, N-[(tricyclo[3.3.1.1^{3,7}]dec-1-yl-oxo)carbonyl]-D-
 phenylalanyl-N-[(3S)-1-[imino[(phenylmethoxy)carbonyl]amino]methyl]-2-oxo-
 3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 150906-25-5 CAPLUS

CN L-Phenylalaninamide, 3-methyl-N-[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]-D-valyl-N-[(3S)-1-[(phenylmethoxy)carbonyl]amino]methyl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 150906-26-6 CAPLUS

CN L-Phenylalaninamide, 3-methyl-N-(tricyclo[3.3.1.13,7]dec-1-ylacetyl)-D-valyl-N-[(3S)-1-[(phenylmethoxy)carbonyl]amino]methyl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 150906-31-3 CAPLUS


CN L-Phenylalaninamide, (2R)-2-tricyclo[3.3.1.13,7]dec-1-yl-N-[(tricyclo[3.3.1.13,7]dec-1-yloxy)carbonyl]glycyl-N-[(3S)-1-[(phenylmethoxy)carbonyl]amino]methyl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212334-19-5 CAPLUS
 CN L-Phenylalaninamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-D-valyl-N-
 [(3S)-1-[imino[(phenylmethoxy)carbonyl]amino]methyl]-2-oxo-3-piperidiny]-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212334-20-8 CAPLUS
 CN L-Phenylalaninamide, N-(methoxycarbonyl)-3-methyl-D-valyl-N-[(3S)-1-
 [imino[(phenylmethoxy)carbonyl]amino]methyl]-2-oxo-3-piperidiny]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 212334-22-0 CAPLUS
 CN L-Phenylalaninamide, N-(ethoxycarbonyl)-3-methyl-D-valyl-N-[(3S)-1-
 [imino[(phenylmethoxy)carbonyl]amino]methyl]-2-oxo-3-piperidiny]- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 212334-24-2 CAPLUS

CN L-Phenylalaninamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-D-valyl-N-[(3S)-1-[imino[(phenylmethoxy)carbonyl]amino]methyl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 212334-26-4 CAPLUS

CN L-Phenylalaninamide, N-[(tricyclo[3.3.1.1.3,7]dec-1-yloxy)carbonyl]-L-valyl-N-[(3S)-1-[imino[(phenylmethoxy)carbonyl]amino]methyl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 212334-28-6 CAPLUS

CN L-Phenylalaninamide, N-[(tricyclo[3.3.1.1.3,7]dec-1-yloxy)carbonyl]-L-leucyl-N-[(3S)-1-[imino[(phenylmethoxy)carbonyl]amino]methyl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 212334-30-0 CAPLUS

CN L-Phenylalaninamide, N-[(tricyclo[3.3.1.1^{3,7}]dec-1-yloxy)carbonyl]-D-valyl-N-[(3S)-1-[imino[(phenylmethoxy)carbonyl]amino]methyl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 212334-32-2 CAPLUS

CN L-Phenylalaninamide, N-[(tricyclo[3.3.1.1^{3,7}]dec-1-yloxy)carbonyl]-D-leucyl-N-[(3S)-1-[imino[(phenylmethoxy)carbonyl]amino]methyl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 212334-34-4 CAPLUS

L-phenylalaninamide, (2R)-2-(2-naphthalenyl)-N-[(tricyclo[3.3.1.1^{3,7}]dec-1-yl-
 oxy)carbonyl]glycyl-N-[(3S)-1-[imino[(phenylmethoxy)carbonyl]amino]meth-
 yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212334-62-8 CAPLUS

CN L-Phenylalaninamide, N-[[[(3,5-dimethyltricyclo[3.3.1.1^{3,7}]dec-1-yl)oxy]carbonyl]-3-methyl-D-valyl-N-[(3S)-1-[[imino[(phenylmethoxy)carbonyl]amino]methyl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

— Me

RN 212334-63-9 CAPLUS

CN L-Phenylalaninamide, 3-methyl-N-[(tricyclo[3.3.1.1^{3,7}]dec-1-yloxy)carbonyl]-D-valyl-N-[(3S)-1-[[imino[(phenylmethoxy)carbonyl]amino]methyl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT